浏览全部资源
扫码关注微信
1.江西中医药大学 院士工作站,南昌 330004
2.中国中医科学院 中药研究所,北京 100700
3.中国中医科学院 中药资源中心,北京 100700
单中超,在读硕士,从事中药药理研究,E-mail:shanzc1996@163.com
李洪梅,研究员,博士生导师,从事中药药理研究及新药开发,E-mail:lihm2006@sina.cn; *
黄璐琦,研究员,博士生导师,从事中药资源与分子生药学研究,E-mail:huangluqi01@126.com
收稿日期:2023-05-06,
网络出版日期:2023-08-01,
纸质出版日期:2023-09-20
移动端阅览
单中超,孙建辉,李建良等.基于转录组学的化湿败毒方治疗流感病毒性肺炎作用机制[J].中国实验方剂学杂志,2023,29(18):54-61.
SHAN Zhongchao,SUN Jianhui,LI Jianliang,et al.Mechanism of Huashi Baidu Prescription in Treating Influenza Viral Pneumonia Based on Transcriptome[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(18):54-61.
单中超,孙建辉,李建良等.基于转录组学的化湿败毒方治疗流感病毒性肺炎作用机制[J].中国实验方剂学杂志,2023,29(18):54-61. DOI: 10.13422/j.cnki.syfjx.20230837.
SHAN Zhongchao,SUN Jianhui,LI Jianliang,et al.Mechanism of Huashi Baidu Prescription in Treating Influenza Viral Pneumonia Based on Transcriptome[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(18):54-61. DOI: 10.13422/j.cnki.syfjx.20230837.
目的
2
明确化湿败毒方对甲型H1N1流感病毒致小鼠肺炎的治疗作用,基于转录组学探讨其作用机制。
方法
2
采用甲型H1N1流感病毒滴鼻感染建立小鼠流感病毒性肺炎模型,连续给药5 d,考察小鼠一般状况、肺指数、病毒载量、肺组织病理形态、生存时间、生存时间延长率等指标,明确化湿败毒方对流感病毒性肺炎的治疗作用。采用转录组学技术检测模型组与正常组、化湿败毒方组与模型组小鼠肺组织的差异表达基因,筛选化湿败毒方治疗流感病毒性肺炎的潜在核心靶点;采用实时荧光定量聚合酶链式反应(Real-time PCR)验证化湿败毒方对核心靶点基因mRNA表达水平的影响。
结果
2
与正常组比较,模型组小鼠肺指数及肺组织内病毒载量均明显升高(
P
<
0.05,
P
<
0.01);与模型组比较,化湿败毒方高剂量组明显延长甲型流感病毒感染小鼠的生存时间(
P
<
0.05),明显降低小鼠肺指数值(
P
<
0.05),降低肺组织病毒载量,化湿败毒方高、中、低剂量组可明显减轻小鼠肺组织炎症、瘀血、肿胀等病变(
P
<
0.05,
P
<
0.01)。肺组织转录组学分析显示,化湿败毒方干预后核心基因主要富集在核转录因子-
κ
B(NF-
κ
B)信号通路、白细胞介素-17(IL-17)信号通路、细胞因子-细胞因子受体相互作用等通路,TNF受体相关因子6(TRAF6)、核转录因子-
κ
B抑制因子
α
(NFKBIA)、趋化因子配体(CCL)2、CCL7、CXC趋化因子配体2(CXCL2)为combined score值前5的节点基因;Real-time PCR验证显示,化湿败毒方能明显下调NF-
κ
B信号通路关键基因TRAF6、NFKBIA及趋化因子CCL2、CCL7、CXCL2 mRNA表达(
P
<
0.05,
P
<
0.01)。
结论
2
化湿败毒方对流感病毒性肺炎具有治疗作用,可能通过抑制NF-
κ
B信号通路关键节点TRAF6、NFKBIA表达,抑制趋化因子CCL2、CCL7、CXCL2的表达,减少炎症细胞的募集,降低病毒载量,发挥抗流感病毒肺炎作用。
Objective
2
To clarify the therapeutic effect of Huashi Baidu prescription on pneumonia in mice caused by influenza A (H1N1) virus and explore its mechanism based on the transcriptome.
Method
2
A mouse influenza viral pneumonia model was built by intranasal infection with influenza A virus, and mice were continuously administered the drug for five days, so as to investigate the general condition, lung index, viral load, pathological morphology of lung tissue, survival time, and prolongation rate of survival time of mice and clarify the therapeutic effect of Huashi Baidu prescription on influenza viral pneumonia. Transcriptome technology was used to detect the differentially expressed genes in the lung tissue of mice in the model group and the normal group, as well as the Huashi Baidu prescription group and the model group, and the potential core target of the Huashi Baidu prescription for the treatment of influenza viral pneumonia was screened. Real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) was used to verify the effect of Huashi Baidu prescription on the mRNA expression level of core target genes.
Result
2
Compared with the normal group, the lung index and viral load in the lung tissue of the model group were significantly increased (
P
<
0.05,
P
<
0.01). Compared with the model group, the high-dose group of Huashi Baidu prescription significantly prolonged the survival time of mice infected with influenza A virus (
P
<
0.05) and significantly reduced the lung index value of mice (
P
<
0.05) and the viral load of lung tissue. The high-dose, medium-dose, and low-dose groups of Huashi Baidu prescription could significantly reduce lung tissue inflammation, blood stasis, swelling, and other pathological changes in mice (
P
<
0.05,
P
<
0.01). Transcriptome analysis of lung tissue showed that core genes were mainly enriched in the nuclear transcription factor-
κ
B (NF-
κ
B) signaling pathway, interleukin-17 (IL-17) signaling pathway, cytokine-cytokine receptor interaction, and other pathways after the intervention of Huashi Baidu prescription. TRAF6, NFKBIA, CCL2, CCL7, and CXCL2 were the top five node genes with combined score values. Real-time PCR validation showed that Huashi Baidu prescription significantly downregulated the mRNA expression of key genes TRAF6 and NFKBIA in the NF-
κ
B signaling pathway, as well as chemokines CCL2, CCL7, and CXCL2 (
P
<
0.05,
P
<
0.01).
Conclusion
2
Huashi Baidu prescription has a therapeutic effect on influenza viral pneumonia, possibly by inhibiting the expression of key nodes TRAF6 and NFKBIA in the NF-
κ
B signaling pathway and that of chemokines CCL2, CCL7, and CXCL2, reducing the recruitment of inflammatory cells and viral load, and exerting anti-influenza viral pneumonia effects.
MOORE K A , OSTROWSKY J T , KRAIGSLEY A M , et al . A research and development (R&D) roadmap for influenza vaccines:Looking toward the future [J]. Vaccine , 2021 , 39 ( 45 ): 6573 - 6584 .
XU H , LI S , LIU J , et al . Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19 [J]. Proc Natl Acad Sci USA , 2023 , 120 ( 18 ): e2301775120 .
XIONG Y , TIAN Y , MA Y , et al . The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19:A retrospective cohort study [J]. Phytomedicine , 2022 , 95 : 153868 .
赵延平 , 吴百灵 . 麻杏石甘汤加减治疗热毒袭肺型流行性感冒临床疗效观察 [J]. 中医药临床杂志 , 2022 , 34 ( 8 ): 1536 - 1539 .
王春红 , 贾琦 , 徐冬梅 . 宣白承气汤加减治疗重症流行性感冒(毒热壅肺证)临床研究 [J]. 湖北中医药大学学报 , 2021 , 23 ( 2 ): 66 - 69 .
黄晶 , 张卫东 , 张锦 . 柴胡达原饮在冬季小儿流行性感冒治疗中的有效性及安全性分析 [J]. 检验医学与临床 , 2020 , 17 ( 20 ): 3018 - 3020 .
吴男芳 , 马兴萍 , 赵秀英 . 藿香正气汤治疗小儿外感发热286例 [J]. 陕西中医 , 1995 , 16 ( 8 ): 362 .
刘清泉 . 中医药在甲型H1N1流感防治中的作用 [J]. 中国中医药现代远程教育 , 2010 , 8 ( 17 ): 168 - 171 .
陈奇 . 中药药理研究方法学 [M]. 2版 . 北京 : 人民卫生出版社 , 2006 : 33 - 34
孙建辉 , 唐纯玉 , 霍海如 , 等 . 喉咽清提取物对流感病毒感染肺炎小鼠模型的保护作用 [J]. 中南药学 , 2019 , 17 ( 8 ): 1229 - 1233 .
孙建辉 , 郝莉雨 , 李宗源 , 等 . 小儿风热清合剂(口服液)对流感病毒致小鼠病毒性肺炎的影响 [J]. 中草药 , 2022 , 53 ( 9 ): 2740 - 2746 .
孙建辉 , 霍海如 , 李小芹 , 等 . 六神丸对非感染性、感染性炎症动物模型抗炎作用研究 [J]. 中国中医药信息杂志 , 2018 , 25 ( 10 ): 60 - 65 .
华旭琳 , 虞刘达 , 董雷 . 轻症流行性感冒的中医药临床研究进展 [J]. 浙江中西医结合杂志 , 2022 , 32 ( 8 ): 776 - 779 .
中华人民共和国国家卫生健康委员会 . 新型冠状病毒肺炎诊疗方案(试行第六版) [J]. 中国感染控制杂志 , 2020 , 19 ( 2 ): 4 .
国家卫生健康委员会办公厅 , 国家中医药管理局办公室 . 新型冠状病毒感染的肺炎诊疗方案(试行第七版) [J]. 全科医学临床与教育 , 2020 , 18 ( 2 ): 100 - 105 .
王恩龙 , 何黎黎 , 李婧 . 基于网络药理学与分子对接技术的化湿败毒颗粒治疗新型冠状病毒肺炎作用机制及活性成分筛选研究 [J]. 亚太传统医药 , 2021 , 17 ( 7 ): 149 - 154 .
SANTORO M G , ROSSI A , AMICI C . NF-kappaB and virus infection:Who controls whom [J]. EMBO J , 2003 , 22 ( 11 ): 2552 - 2560 .
GALIBERT L , TOMETSKO M E , ANDERSON D M , et al . The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB,a member of the TNFR superfamily [J]. J Biol Chem , 1998 , 273 ( 51 ): 34120 - 34127 .
CHEN L F , WILLIAMS S A , MU Y , et al . NF-kappaB RelA phosphorylation regulates RelA acetylation [J]. Mol Cell Biol , 2005 , 25 ( 18 ): 7966 - 7975 .
SERBINA N V , SHI C , PAMER E G . Monocyte-mediated immune defense against murine Listeria monocytogenes infection [J]. Adv Immunol , 2012 , 113 : 119 - 134 .
TSOU C L , PETERS W , SI Y , et al . Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites [J]. J Clin Invest , 2007 , 117 ( 4 ): 902 - 909 .
LIU S , LIU J , YANG X , et al . Cis-acting lnc-CXCL2 restrains neutrophil-mediated lung inflammation by inhibiting epithelial cell CXCL2 expression in virus infection [J]. Proc Natl Acad Sci USA , 2021 , 118 ( 41 ): e2108276118 .
0
浏览量
35
下载量
6
CSCD
关联资源
相关文章
相关作者
相关机构